• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    6/11/24 12:31:11 PM ET
    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million.
    • Trinity Biotech (NASDAQ:TRIB) stock rose 20.61% to $2.75. The company's market cap stands at $26.0 million.
    • Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 20.26% to $3.03. The company's market cap stands at $35.5 million.
    • Kronos Bio (NASDAQ:KRON) shares increased by 16.71% to $1.11. The market value of their outstanding shares is at $66.7 million.
    • Black Diamond Therapeutic (NASDAQ:BDTX) shares increased by 15.72% to $5.91. The market value of their outstanding shares is at $332.7 million.
    • Streamline Health Solns (NASDAQ:STRM) shares moved upwards by 14.85% to $0.53. The market value of their outstanding shares is at $32.8 million. As per the news, the Q1 earnings report came out today.

    Losers

    • ProKidney (NASDAQ:PROK) stock decreased by 25.2% to $2.26 during Tuesday's regular session. The company's market cap stands at $144.3 million.
    • BioSig Technologies (NASDAQ:BSGM) stock decreased by 14.8% to $1.44. The company's market cap stands at $20.3 million.
    • Inspire Veterinary (NASDAQ:IVP) stock declined by 14.07% to $1.65. The company's market cap stands at $1.6 million.
    • Aethlon Medical (NASDAQ:AEMD) stock decreased by 10.8% to $0.5. The market value of their outstanding shares is at $2.5 million.
    • Theriva Biologics (AMEX:TOVX) stock fell 10.74% to $0.23. The company's market cap stands at $3.9 million.
    • CareCloud (NASDAQ:CCLD) shares declined by 10.42% to $2.88. The market value of their outstanding shares is at $46.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $AKTX
    $BDTX
    $BSGM

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    More analyst ratings

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Neal James R

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    3/16/26 5:00:03 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,613 shares, increasing direct ownership by 8% to 109,821 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/12/26 5:00:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 5,123 shares, increasing direct ownership by 2% to 472,067 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/12/26 5:00:12 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    SEC Filings

    View All

    SEC Form S-8 filed by ProKidney Corp.

    S-8 - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:07:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:03:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by ProKidney Corp.

    10-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:01:34 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProKidney Reports Full Year 2025 Financial Results and Business Highlights

    On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("Pro

    3/18/26 4:00:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

    TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulne

    3/18/26 8:05:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

    Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column

    3/12/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AKTX
    $BDTX
    $BSGM
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care